Inhibition of ecto-ATPase by PPADS, suramin and reactive blue in endothelial cells, C6 glioma cells and RAW 264.7 macrophages

Bin C. Chen, Chii M. Lee, Wan W. Lin

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

1. Previous studies have shown that bovine pulmonary artery endothelium (CPAE) has P(2Y) and P(2U) purinoceptors, rat C6 glioma cells have P(2U) purinoceptors and mouse RAW 264.7 cells have pyrimidinoceptors, all of which are coupled to phosphoinositide-specific phospholipase C (PI-PLC). The dual actions of PPADS, suramin and reactive blue as antagonists of receptor subtypes and ecto-ATPase inhibitors were studied in these three cell types. 2. In CPAE, suramin, at 3-100 μM, competitively inhibited the PI responses induced by 2MeSATP and UTP, with pA2 values of 5.5 ± 0.3 and 4.4 ± 0.4, respectively. Reactive blue, at 1-3 μM, produced shifts to the right of the 2MeSATP and UTP curves, but no further right shift at 10 μM. PPADS, at 10 μM, caused a 3 fold right shift of the 2MeSATP curve, but no further shift at concentrations up to 100 μM. In contrast, a dose-dependent shift to the left of the UTP curve and a weak inhibition of the ATP response were seen with PPADS. 3. In RAW 264.7 cells, suramin and reactive blue, but not PPADS, competitively inhibited the UTP response, with pA2 values of 4.8 ± 0.5 and 5.8 ± 0.7, respectively. 4. In C6 glioma cells, although suramin and reactive blue inhibited the ATP response, a potentiation effect on ATP and UTP responses was seen with PPADS. 5. The ecto-ATPase inhibitory activity of these three receptor antagonists were determined. All three inhibited ecto-ATPase present in CPAE, C6 and RAW 264.7 cells, with IC50 values of 4, 4.8 and 4.7 for PPADS, 4, 4.4 and >> 4 for suramin, and 4.5, 4.7 and 4.7 for reactive blue. 6. This study indicates that PPADS, suramin and reactive blue are ecto-ATPase inhibitors. This property, combined with their antagonistic selectivity for receptor subtypes, can result in inhibition of, potentiation of, or lack of effect on agonist-mediated PI responses. Reactive blue is a more potent antagonist than suramin on P(2Y), P(2U) and pyrimidinoceptors, and PPADS is a weak antagonist for P(2Y) receptors.

Original languageEnglish
Pages (from-to)1628-1634
Number of pages7
JournalBritish Journal of Pharmacology
Volume119
Issue number8
Publication statusPublished - 1996
Externally publishedYes

Fingerprint

Suramin
Glioma
Endothelial Cells
Uridine Triphosphate
Macrophages
Purinergic Receptors
Adenosine Triphosphate
Phosphoinositide Phospholipase C
RAW 264.7 Cells
pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid
ectoATPase
Pulmonary Artery
Inhibitory Concentration 50
Endothelium

Keywords

  • Ecto-ATPase
  • P(2U)-purinoceptor
  • P(2Y)-purinoceptor
  • PPADS
  • Pyrimidinoceptor
  • Reactive blue
  • Receptor antagonist
  • Suramin

ASJC Scopus subject areas

  • Pharmacology

Cite this

Inhibition of ecto-ATPase by PPADS, suramin and reactive blue in endothelial cells, C6 glioma cells and RAW 264.7 macrophages. / Chen, Bin C.; Lee, Chii M.; Lin, Wan W.

In: British Journal of Pharmacology, Vol. 119, No. 8, 1996, p. 1628-1634.

Research output: Contribution to journalArticle

@article{d5fd6033084549f28394d8c7106f3237,
title = "Inhibition of ecto-ATPase by PPADS, suramin and reactive blue in endothelial cells, C6 glioma cells and RAW 264.7 macrophages",
abstract = "1. Previous studies have shown that bovine pulmonary artery endothelium (CPAE) has P(2Y) and P(2U) purinoceptors, rat C6 glioma cells have P(2U) purinoceptors and mouse RAW 264.7 cells have pyrimidinoceptors, all of which are coupled to phosphoinositide-specific phospholipase C (PI-PLC). The dual actions of PPADS, suramin and reactive blue as antagonists of receptor subtypes and ecto-ATPase inhibitors were studied in these three cell types. 2. In CPAE, suramin, at 3-100 μM, competitively inhibited the PI responses induced by 2MeSATP and UTP, with pA2 values of 5.5 ± 0.3 and 4.4 ± 0.4, respectively. Reactive blue, at 1-3 μM, produced shifts to the right of the 2MeSATP and UTP curves, but no further right shift at 10 μM. PPADS, at 10 μM, caused a 3 fold right shift of the 2MeSATP curve, but no further shift at concentrations up to 100 μM. In contrast, a dose-dependent shift to the left of the UTP curve and a weak inhibition of the ATP response were seen with PPADS. 3. In RAW 264.7 cells, suramin and reactive blue, but not PPADS, competitively inhibited the UTP response, with pA2 values of 4.8 ± 0.5 and 5.8 ± 0.7, respectively. 4. In C6 glioma cells, although suramin and reactive blue inhibited the ATP response, a potentiation effect on ATP and UTP responses was seen with PPADS. 5. The ecto-ATPase inhibitory activity of these three receptor antagonists were determined. All three inhibited ecto-ATPase present in CPAE, C6 and RAW 264.7 cells, with IC50 values of 4, 4.8 and 4.7 for PPADS, 4, 4.4 and >> 4 for suramin, and 4.5, 4.7 and 4.7 for reactive blue. 6. This study indicates that PPADS, suramin and reactive blue are ecto-ATPase inhibitors. This property, combined with their antagonistic selectivity for receptor subtypes, can result in inhibition of, potentiation of, or lack of effect on agonist-mediated PI responses. Reactive blue is a more potent antagonist than suramin on P(2Y), P(2U) and pyrimidinoceptors, and PPADS is a weak antagonist for P(2Y) receptors.",
keywords = "Ecto-ATPase, P(2U)-purinoceptor, P(2Y)-purinoceptor, PPADS, Pyrimidinoceptor, Reactive blue, Receptor antagonist, Suramin",
author = "Chen, {Bin C.} and Lee, {Chii M.} and Lin, {Wan W.}",
year = "1996",
language = "English",
volume = "119",
pages = "1628--1634",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "John Wiley and Sons Inc.",
number = "8",

}

TY - JOUR

T1 - Inhibition of ecto-ATPase by PPADS, suramin and reactive blue in endothelial cells, C6 glioma cells and RAW 264.7 macrophages

AU - Chen, Bin C.

AU - Lee, Chii M.

AU - Lin, Wan W.

PY - 1996

Y1 - 1996

N2 - 1. Previous studies have shown that bovine pulmonary artery endothelium (CPAE) has P(2Y) and P(2U) purinoceptors, rat C6 glioma cells have P(2U) purinoceptors and mouse RAW 264.7 cells have pyrimidinoceptors, all of which are coupled to phosphoinositide-specific phospholipase C (PI-PLC). The dual actions of PPADS, suramin and reactive blue as antagonists of receptor subtypes and ecto-ATPase inhibitors were studied in these three cell types. 2. In CPAE, suramin, at 3-100 μM, competitively inhibited the PI responses induced by 2MeSATP and UTP, with pA2 values of 5.5 ± 0.3 and 4.4 ± 0.4, respectively. Reactive blue, at 1-3 μM, produced shifts to the right of the 2MeSATP and UTP curves, but no further right shift at 10 μM. PPADS, at 10 μM, caused a 3 fold right shift of the 2MeSATP curve, but no further shift at concentrations up to 100 μM. In contrast, a dose-dependent shift to the left of the UTP curve and a weak inhibition of the ATP response were seen with PPADS. 3. In RAW 264.7 cells, suramin and reactive blue, but not PPADS, competitively inhibited the UTP response, with pA2 values of 4.8 ± 0.5 and 5.8 ± 0.7, respectively. 4. In C6 glioma cells, although suramin and reactive blue inhibited the ATP response, a potentiation effect on ATP and UTP responses was seen with PPADS. 5. The ecto-ATPase inhibitory activity of these three receptor antagonists were determined. All three inhibited ecto-ATPase present in CPAE, C6 and RAW 264.7 cells, with IC50 values of 4, 4.8 and 4.7 for PPADS, 4, 4.4 and >> 4 for suramin, and 4.5, 4.7 and 4.7 for reactive blue. 6. This study indicates that PPADS, suramin and reactive blue are ecto-ATPase inhibitors. This property, combined with their antagonistic selectivity for receptor subtypes, can result in inhibition of, potentiation of, or lack of effect on agonist-mediated PI responses. Reactive blue is a more potent antagonist than suramin on P(2Y), P(2U) and pyrimidinoceptors, and PPADS is a weak antagonist for P(2Y) receptors.

AB - 1. Previous studies have shown that bovine pulmonary artery endothelium (CPAE) has P(2Y) and P(2U) purinoceptors, rat C6 glioma cells have P(2U) purinoceptors and mouse RAW 264.7 cells have pyrimidinoceptors, all of which are coupled to phosphoinositide-specific phospholipase C (PI-PLC). The dual actions of PPADS, suramin and reactive blue as antagonists of receptor subtypes and ecto-ATPase inhibitors were studied in these three cell types. 2. In CPAE, suramin, at 3-100 μM, competitively inhibited the PI responses induced by 2MeSATP and UTP, with pA2 values of 5.5 ± 0.3 and 4.4 ± 0.4, respectively. Reactive blue, at 1-3 μM, produced shifts to the right of the 2MeSATP and UTP curves, but no further right shift at 10 μM. PPADS, at 10 μM, caused a 3 fold right shift of the 2MeSATP curve, but no further shift at concentrations up to 100 μM. In contrast, a dose-dependent shift to the left of the UTP curve and a weak inhibition of the ATP response were seen with PPADS. 3. In RAW 264.7 cells, suramin and reactive blue, but not PPADS, competitively inhibited the UTP response, with pA2 values of 4.8 ± 0.5 and 5.8 ± 0.7, respectively. 4. In C6 glioma cells, although suramin and reactive blue inhibited the ATP response, a potentiation effect on ATP and UTP responses was seen with PPADS. 5. The ecto-ATPase inhibitory activity of these three receptor antagonists were determined. All three inhibited ecto-ATPase present in CPAE, C6 and RAW 264.7 cells, with IC50 values of 4, 4.8 and 4.7 for PPADS, 4, 4.4 and >> 4 for suramin, and 4.5, 4.7 and 4.7 for reactive blue. 6. This study indicates that PPADS, suramin and reactive blue are ecto-ATPase inhibitors. This property, combined with their antagonistic selectivity for receptor subtypes, can result in inhibition of, potentiation of, or lack of effect on agonist-mediated PI responses. Reactive blue is a more potent antagonist than suramin on P(2Y), P(2U) and pyrimidinoceptors, and PPADS is a weak antagonist for P(2Y) receptors.

KW - Ecto-ATPase

KW - P(2U)-purinoceptor

KW - P(2Y)-purinoceptor

KW - PPADS

KW - Pyrimidinoceptor

KW - Reactive blue

KW - Receptor antagonist

KW - Suramin

UR - http://www.scopus.com/inward/record.url?scp=0030474864&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030474864&partnerID=8YFLogxK

M3 - Article

VL - 119

SP - 1628

EP - 1634

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 8

ER -